These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22578690)

  • 21. Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours.
    Moore AS; Frimberger AE; Taylor D; Sullivan N
    Vet Comp Oncol; 2020 Sep; 18(3):402-408. PubMed ID: 31916687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
    Kiupel M; Webster JD; Miller RA; Kaneene JB
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
    Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
    BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the global DNA methylation in canine mast cell tumour samples by immunostaining of 5-methyl cytosine.
    Morimoto CY; Tedardi MV; da Fonseca IIM; Kimura KC; Sanches DS; Epiphanio TF; de Francisco Strefezzi R; Dagli MLZ
    Vet Comp Oncol; 2017 Sep; 15(3):1014-1018. PubMed ID: 27140659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone.
    Webster JD; Yuzbasiyan-Gurkan V; Thamm DH; Hamilton E; Kiupel M
    BMC Vet Res; 2008 Aug; 4():32. PubMed ID: 18700956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of molecular genetic contributants to canine cutaneous mast cell tumour metastasis by global gene expression analysis.
    Bowlt Blacklock K; Birand Z; Biasoli D; Fineberg E; Murphy S; Flack D; Bass J; Di Palma S; Blackwood L; McKay J; Whitbread T; Fox R; Eve T; Beaver S; Starkey M
    PLoS One; 2018; 13(12):e0208026. PubMed ID: 30566430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of intratumoral vessel density in cutaneous mast cell tumors of the dog.
    Preziosi R; Sarli G; Paltrinieri M
    J Comp Pathol; 2004; 130(2-3):143-51. PubMed ID: 15003472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
    Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
    Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours.
    Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE
    Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicancer-like syndrome in a dog characterized by p53 and cell cycle-checkpoint kinase 2 (CHK2) mutations and sirtuin gene (SIRT1) down-regulation.
    Marfe G; De Martino L; Tafani M; Irno-Consalvo M; Pasolini MP; Navas L; Papparella S; Gambacurta A; Paciello O
    Res Vet Sci; 2012 Aug; 93(1):240-5. PubMed ID: 21890154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
    Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM
    Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
    Smrkovski OA; Essick L; Rohrbach BW; Legendre AM
    Vet Comp Oncol; 2015 Sep; 13(3):314-21. PubMed ID: 23845124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canine subcutaneous mast cell tumour: diagnosis and prognosis.
    Newman SJ; Mrkonjich L; Walker KK; Rohrbach BW
    J Comp Pathol; 2007 May; 136(4):231-9. PubMed ID: 17399734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptomic analysis identified up-regulation of a solute carrier transporter and UDP glucuronosyltransferases in dogs with aggressive cutaneous mast cell tumours.
    Giantin M; Baratto C; Marconato L; Vascellari M; Mutinelli F; Dacasto M; Granato A
    Vet J; 2016 Jun; 212():36-43. PubMed ID: 27256023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical Expression of the Pluripotency Factor OCT4 in Canine Mast Cell Tumours.
    Vargas TH; Pulz LH; Barra CN; Kleeb SR; Xavier JG; Catão-Dias JL; Fukumasu H; Nishiya AT; Strefezzi RF
    J Comp Pathol; 2015 Nov; 153(4):251-5. PubMed ID: 26460092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global gene expression analysis of canine cutaneous mast cell tumor: could molecular profiling be useful for subtype classification and prognostication?
    Giantin M; Granato A; Baratto C; Marconato L; Vascellari M; Morello EM; Vercelli A; Mutinelli F; Dacasto M
    PLoS One; 2014; 9(4):e95481. PubMed ID: 24748173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features.
    Horta RS; Lavalle GE; Monteiro LN; Souza MCC; Cassali GD; Araújo RB
    Vet Pathol; 2018 Mar; 55(2):212-223. PubMed ID: 29338615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012).
    Pratschke KM; Atherton MJ; Sillito JA; Lamm CG
    J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours.
    Macfarlane MJ; Macfarlane LL; Scase T; Parkin T; Morris JS
    Vet Rec; 2016 Nov; 179(19):491. PubMed ID: 27650464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apoptotic intrinsic pathway proteins predict survival in canine cutaneous mast cell tumours.
    Barra CN; Macedo BM; Cadrobbi KG; Pulz LH; Huete GC; Kleeb SR; Xavier JG; Catão-Dias JL; Nishiya AT; Fukumasu H; Strefezzi RF
    Vet Comp Oncol; 2018 Mar; 16(1):E38-E44. PubMed ID: 28608404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.